Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been assigned a $20.00 target price by Wells Fargo & Company in a research note issued to investors on Wednesday. The brokerage presently has a “hold” rating on the stock. Wells Fargo & Company’s target price suggests a potential upside of 27.55% from the company’s previous close.

Several other equities research analysts also recently weighed in on the company. Morgan Stanley set a $15.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a “sell” rating in a report on Thursday. Cowen and Company reissued a “market perform” rating and issued a $18.00 price target (down previously from $30.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Maxim Group reissued a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Zacks Investment Research raised Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “hold” rating in a report on Wednesday. Finally, Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Five research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $28.72.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 2.49% during trading on Wednesday, reaching $15.68. The company’s stock had a trading volume of 37,585,420 shares. The firm’s 50-day moving average is $16.94 and its 200-day moving average is $26.89. The stock’s market capitalization is $15.93 billion. Teva Pharmaceutical Industries Limited has a 12-month low of $15.22 and a 12-month high of $45.85. Teva Pharmaceutical Industries Limited also was the target of unusually large options trading on Wednesday. Stock investors acquired 29,656 put options on the stock. This is an increase of approximately 231% compared to the typical volume of 8,957 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.06 by ($0.07). The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.25 EPS. Equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.28 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Wells Fargo & Company Reiterates $20.00 Price Target for Teva Pharmaceutical Industries Limited (TEVA)” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/05/wells-fargo-company-reiterates-20-00-price-target-for-teva-pharmaceutical-industries-limited-teva.html.

Several institutional investors have recently bought and sold shares of the company. Perpetual Ltd purchased a new stake in shares of Teva Pharmaceutical Industries Limited in the second quarter valued at approximately $2,865,000. WFG Advisors LP increased its position in shares of Teva Pharmaceutical Industries Limited by 2,650.1% in the second quarter. WFG Advisors LP now owns 29,784 shares of the company’s stock valued at $989,000 after buying an additional 28,701 shares in the last quarter. Oak Associates Ltd. OH increased its position in shares of Teva Pharmaceutical Industries Limited by 0.6% in the second quarter. Oak Associates Ltd. OH now owns 379,924 shares of the company’s stock valued at $12,621,000 after buying an additional 2,114 shares in the last quarter. Cetera Investment Advisers purchased a new stake in shares of Teva Pharmaceutical Industries Limited in the second quarter valued at approximately $373,000. Finally, Sterneck Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 5.4% in the second quarter. Sterneck Capital Management LLC now owns 131,907 shares of the company’s stock valued at $4,382,000 after buying an additional 6,702 shares in the last quarter. Institutional investors and hedge funds own 56.77% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.